Baldo brings 20 years of experience in both technology and therapeutics, combined with expertise in organisational design and change, including his most recent role as senior vice president and head of US medical affairs at Genentech, Inc., a member of the Roche Group.
During Baldo's tenure at Genentech, he oversaw the successful medical launch of a number of new medicines, including Hemlibra (emicizumab-kxwh), a novel treatment for hemophilia A, and Ocrevus (ocrelizumab), the first B-cell therapy specifically indicated for multiple sclerosis.
Dr. Baldo also led the Medical Affairs division through an agile transformation, focusing on driving towards individual empowerment, broadening roles, and revamping the field medical team all in the service of better patient outcomes and customer engagement.
Before becoming head of US medical affairs, he was franchise head for ophthalmology, overseeing the launch of two new indications for Lucentis.
He was general manager for Roche Pharma in New Zealand, and he also served as a lifecycle leader and as a global medical director for Roche Global Product Strategy/Global Medical Affairs in Basel, Switzerland.
Before joining Roche, Baldo was the global vice president of medical science and affairs for The Medicines Company in Parsippany, NJ, and he founded a venture capital-backed medical software company MedAptus, Inc. where he was Chief Medical officer and capital fundraiser.
Adaptive Biotechnologies is in immune-driven medicine.
Adaptive's proprietary immune medicine platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision.
Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products designed to transform the way diseases such as cancer, autoimmune conditions, and infectious diseases are diagnosed and treated.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial